Monitor for FDA's ODD decision within ~90 days (by late December 2026). A grant would be a modest positive catalyst; a denial would be a setback. Also watch for interim data from the ongoing Phase 2a MSA trial and the Phase 2a SPMS trial for efficacy signals.
Price Chart
Executive Summary
Tiziana Life Sciences announced it has submitted a request to the FDA for Orphan Drug Designation (ODD) for intranasal foralumab for the treatment of Multiple System Atrophy (MSA), a rare neurodegenerative disease with no approved disease-modifying therapies. The FDA's OOPD aims to complete review within 90 days; if granted, benefits include 7-year market exclusivity upon approval, tax credits, and fee waivers. This is a regulatory milestone for a pipeline expansion into a new indication, but the Phase 2a trial (NCT06868628) is early-stage open-label with no efficacy data reported yet.
Key Facts
- Tiziana submitted an ODD request to the FDA for intranasal foralumab for MSA on September 30, 2026.
- MSA has no FDA-approved disease-modifying therapies; median survival is 6-9 years.
- FDA OOPD aims to complete ODD review within 90 days of receipt.
- If granted, ODD provides 7-year market exclusivity upon approval, tax credits, and fee waivers.
- Intranasal foralumab is currently in a Phase 2a open-label trial (NCT06868628) in MSA, assessing microglial activation via PET imaging, clinical outcomes, and safety over 6 months.
- The Phase 2a trial is conducted at Brigham and Women's Hospital under PI Vikram Khurana, MD, PhD.
- 14 patients with na-SPMS have been dosed in an Expanded Access Program with improvement or stability seen within 6 months in all patients.
- Additional Phase 2 trials are ongoing in non-active SPMS (randomized, double-blind, placebo-controlled) and Alzheimer's disease.
Financial Impact
No financial figures disclosed; ODD is a regulatory milestone with no immediate revenue impact. Potential 7-year exclusivity upon future approval is a long-term value driver.
Risk Factors
- ODD is not guaranteed; the FDA may deny the request.
- Phase 2a MSA trial is open-label with no control arm, limiting interpretability of efficacy data.
- Foralumab is early-stage for MSA; no clinical data in this indication has been reported.
- Tiziana is a clinical-stage biotech with no approved products and likely limited cash runway (no financial data in this filing).
Investment Themes
Documents Analyzed
This report is based on 5 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 6-K Filing (Primary) | 0001213900-26-104868 |
| Document: ea0307188-6k_tiziana.htm | 0001213900-26-104868 |
| Document: 0001213900-26-104868-index-headers.html | 0001213900-26-104868 |
| Document: 0001213900-26-104868-index.html | 0001213900-26-104868 |
| Document: 0001213900-26-104868.txt | 0001213900-26-104868 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Oct 21, 2026 5d ago | 6-K | $1.01 | awaiting T+20 | — | $0.8907 (−11.81%) |
Oct 16, 2026 9d ago | 6-K | $1.01 | awaiting T+20 | — | $0.8907 (+11.81%) |
Oct 16, 2026 10d ago | 6-K | $1.05 | awaiting T+20 | — | $0.8907 (−15.17%) |
Sep 30, 2026 26d ago | 6-K | $1.11 | awaiting T+20 | — | $0.8907 (−19.76%) |
Sep 28, 2026 28d ago | 6-K | $0.9800 | awaiting T+20 | — | $0.8907 (−9.11%) |
Sep 21, 2026 5w ago | 6-K | $0.9046 $1.01 | ▲ +11.65% | ▲ +12.56% | $0.8907 (−1.54%) |
Sep 17, 2026 5w ago | 6-K | $0.9700 $1.05 | ▲ +8.25% | ▲ +7.04% | $0.8907 (−8.18%) |
Sep 17, 2026 5w ago | Press Release | $0.9700 $1.05 | ▲ +8.25% | ▲ +7.04% | $0.8907 (−8.18%) |
Aug 24, 2026 9w ago | 6-K | $1.15 $0.8899 | ▼ −22.62% | ▼ −23.93% | $0.8907 (−22.55%) |
Aug 6, 2026 11w ago | 6-K | $0.9700 $0.9745 | ▲ +0.46% | ▼ −0.14% | $0.8907 (−8.18%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers